98%
921
2 minutes
20
The growing impact of climate change has highlighted the importance of effective disaster housing recovery (DHR) measures, particularly in resource-constrained places prone to flooding. As these communities confront displacement and financial instability, allocating resources for post-DHR is crucial. This study presents an innovative strategy for improving DHR planning and execution that uses genetic algorithms (GAs), with a focus on Long-Term Recovery Groups (LTRGs) and community engagement for long-term results. By utilizing adaptive capabilities of GAs, the model efficiently navigates the complexity of resource allocation, balancing several criteria, such as cost-effectiveness, housing coverage, and stakeholder needs. This study evaluates the efficacy of GAs in DHR planning by developing and evaluating hypotheses on optimization, LTRG preparedness, and community autonomy. The results show that GA-driven planning considerably improves resource allocation decisions, promoting resilience and long-term recovery. The findings highlight the ability of GAs to solve complex difficulties in DHR, providing insights for policymakers, urban planners, and disaster response teams looking to improve recovery processes and community -resilience.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5055/jem.0906 | DOI Listing |
Mil Med
September 2025
Extremity Trauma and Amputation Center of Excellence, Defense Health Agency, Falls Church, Virginia 22042, United States.
Introduction: An estimated 5.6 million individuals in the U.S.
View Article and Find Full Text PDFAnn Hematol
September 2025
Institute for Workflow-Management in Health Care, European University of Applied Sciences, Cologne, Germany.
In patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who are either refractory to first-line therapy or relapse within 12 months, chimeric antigen receptor (CAR) T-cell therapy is more effective than salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) as second-line therapy. Adoption of CAR T-cell therapy into routine clinical practice involves a period of adaptation and refinement of clinical processes. We aimed to document the evolution of clinical processes for CAR T-cell therapy during 2022 and 2023, and compare healthcare resource utilization (HCRU) associated with CAR T-cell and ASCT processes in routine clinical practice.
View Article and Find Full Text PDFMol Plant
September 2025
Department of Microbiology and Cell Science, University of Florida, P.O. Box 110700, Gainesville, FL 32611, USA. Electronic address:
The plant immune system relies on a precisely balanced interplay between activation and repression to effectively combat pathogens without incurring self-damage. The salicylic acid (SA) signaling pathway, a cornerstone of this system, is currently experiencing a research renaissance. Landmark studies have recently elucidated the complete enzymatic pathways for SA biosynthesis from both chorismate and phenylalanine (Liu et al.
View Article and Find Full Text PDFBr Dent J
September 2025
Managing Senior Physician, Department of Oral and Maxillofacial Surgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Introduction The COVID-19 pandemic significantly disrupted healthcare systems worldwide, including in Germany. This study investigated the impact of the pandemic on the management of dental abscesses and examined the implications for the upcoming German healthcare reform.Aims To assess how the COVID-19 pandemic affected hospitalisation, intensive care unit (ICU) admissions and treatment outcomes for dental abscesses, and to analyse the relationships between these findings and the German healthcare reform.
View Article and Find Full Text PDFJ Am Med Dir Assoc
September 2025
Centre for Optimisation of Medicines, School of Allied Health, The University of Western Australia, Perth, Western Australia, Australia.
Objectives: To characterize annual trends in prescription medicine dispensing patterns among Australians ≥65 years of age from 2013-2023.
Design: Population-based retrospective descriptive study.
Setting And Participants: A 10% sample of the Australian Pharmaceutical Benefits Scheme (PBS) dataset covering medicines dispensed between 2013 and 2023.